Infection and Drug Resistance (Jan 2024)

Insights into the in-vitro Susceptibility and Drug–Drug Interaction Profiles Against Drug-Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates in Amhara, Ethiopia

  • Seid A,
  • Girma Y,
  • Dereb E,
  • Kassa M,
  • Nureddin S,
  • Abebe A,
  • Berhane N

Journal volume & issue
Vol. Volume 17
pp. 89 – 107

Abstract

Read online

Aynias Seid,1,2 Yilak Girma,3 Eseye Dereb,3 Meseret Kassa,3 Semira Nureddin,4 Ayenesh Abebe,3 Nega Berhane2 1Department of Biology, College of Natural and Computational Science, Debre-Tabor University, Debre-Tabor, Ethiopia; 2Department of Medical Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia; 3TB Culture Laboratory, University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia; 4Department of Biology, College of Natural and Computational Science, Woldia University, Woldia, EthiopiaCorrespondence: Aynias Seid, Email [email protected]: In Ethiopia, tuberculosis (TB) is a major public health problem. The aim of the study was to determine the in vitro susceptibility level of drugs and drug interaction profiles against drug-resistant and susceptible M. tuberculosis clinical isolates. A laboratory-based cross-sectional study was conducted between January 2023 and August 2023. GenoType MTBDRplus v.2.0 was facilitated in genetic mutation detection. Minimum inhibitory concentration (MIC) was determined using resazurin microtitre assay (REMA), while fractional inhibitory concentration index (FICI) using resazurin drug combination microtitre assay (REDCA) for in vitro quantitative susceptibility and drug interaction prediction.Results: Among 32 clinical isolates, a total of 14 (43.8%) RIF, 20 (62.5%) INH, 2 (6.3%) EMB-related resistant and 14 (43.8%) MDR isolates were identified. Five of RIF-resistant isolates (55.6%) carrying rpoB common mutations at codon S450L were associated with high levels of RIF-resistance with MICs of ≥ 2μg/mL, whereas 100% of isolates harboring rpoB substitutions at codons D435V and H445Y were linked with moderate or low-level RIF-resistance in the MIC ranges from 0.5 to 1μg/mL. A proportion of 81.8% of isolates harboring katG S315T mutations were associated with high-level INH resistance (MIC ≥ 1μg/mL), while the 18.2% of isolates with S315T katG mutations and 100% of isolates with inhA C-15T mutations were linked to the low-level of INH resistance with MIC variability from 0.25 to 0.5μg/mL. Our results indicated that most FICIs of the dual drugs INH+RIF and INH+LEV combination for 9 (28.1%) and 4 (12.5%) INH-resistant isolates, respectively, were ≤ 0.5, whereas triple drugs INH+RIF+EMB, INH+RIF+LEV and INH+EMB+LEV combination for 6 (18.8%), 11 (34.4%) and 8 (25%) INH-resistant isolates were from 0.62 to 0.75, all showed synergistic effect.Conclusion: The study highlights that isolates with rpoB S450L and katG S315T substitutions were associated with high level of RIF and INH resistance. It is concluded that REDCA can quantitatively determine anti-mycobacterial synergy and that LEV being of potential use against INH-resistant isolates including MDR-TB when combined with RIF+INH and INH+EMB.Keywords: drug combination, drug interaction, MIC, mutations, synergism

Keywords